The "Ophthalmology Drugs Market Global Briefing 2017" report has been added to Research and Markets' offering.

The global ophthalmology drugs market is expected to reach around $33 billion in 2020.

The ophthalmology drugs market covers drugs that are used in the treatment of eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular degeneration. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax.

This can be attributed to the expected rise in prevalence of eye conditions such as age-related macular degeneration (AMD), diabetic retinopathy and glaucoma that require ophthalmology drugs.

Rho-Kinase Inhibitors In Glaucoma Treatment - Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression.

These inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition.

Major Rho-kinase inhibitors being developed include ATS907, ATS8535, AR-12286, AR-13324, AMA0076 and BOL-303259-X.

Scope:

  • Markets Covered: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs.
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Allergan Plc.
  • Valeant Pharmaceuticals Intl Inc.
  • Bayer AG
  • Santen Pharmaceutical Co. Ltd.
  • Gilead
  • Otsuka Pharmaceutical Co. Ltd.
  • Shire Plc.

For more information about this report visit https://www.researchandmarkets.com/research/9pgz3s/global?w=4